<DOC>
	<DOCNO>NCT01567995</DOCNO>
	<brief_summary>This multicenter , randomise , double-blind , two treatment arm , vehicle ( cream base ) -controlled , parallel-group study subject moderate severe eczema ( defined investigator global assessment ( IGA ) score great equal 3 ) . Subjects screen within 3 day prior randomization . At screen visit , subject give inform consent assess health status eligibility inclusion study . At baseline visit , subject eligibility assess randomization ( Day 0 ) . Eligible subject randomise Clobetasone Butyrate 0.05 % Cream group vehicle ( cream base ) group rate 1:1 . During treatment phase , subject return site day 7 post-baseline visit assessment disease status eligibility continue study . During final visit , 14 day baseline , subject return study site assessment disease status complete study . In addition , safety tolerability Clobetasone Butyrate 0.05 % cream also assess whole trial .</brief_summary>
	<brief_title>Randomised , Double-blind , Placebo-controlled Study Topical Clobetasone Butyrate 0.05 % Cream Subjects With Eczema Two Weeks Evaluate Efficacy Safety</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<mesh_term>Clobetasone butyrate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Subjects diagnosis eczema , fulfil 3 follow item : 1 ) Erythema , papilla/water blister , Lichenification , skin damage infiltration , 2 ) unknown reason , recurrent attack ; 3 ) itching diseased skin Subjects must body surface area ( BSA ) disease involvement less equal 10 % assessed palm method Subject must present moderate eczema define score great equal 3 use investigator global assessment ( IGA ) eczema severity . The subject present systemic disorder active skin disease ( e.g . psoriasis ) would way confound interpretation study result subject present scar , mole , tattoo , body piercings , sunburn test area could interfere assessment lesion screen . The subject eczema restrict face , foot hand . The subject indicate antiinfectives drug current complication overt bacterial , fungal viral infection History recent ( &lt; 1 month ) active presence current superficial skin infection viral aetiology herpes simplex , varicella . The subject expose therapy within set timeframe : Topical agent administer diseased skin , include emollient 1 week ; Systemic administration antihistamine agent 2 week ; Systemic administration corticosteroid 4 week ; Systemic administration immunosuppressive drug 4 week ; UV therapy 4 week Foreseeable intensive ultraviolet ( UV ) exposure study ( solar artificial ) . Subjects must expose intense direct sunlight long period , must use skin tanning device ( e.g . sunbed ) duration study . History clinically significant cardiovascular , pulmonary , gastrointestinal , liver , neurological , renal haematological abnormality . History allergy component test medication use study . History anaphylaxis ( sudden , potentially lifethreatening systemic allergic reaction ) food , medication , insect venom , latex .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>eczematous</keyword>
	<keyword>dermatitis</keyword>
</DOC>